How Evaluate Helps
Dealmaking is the lifeblood of the pharma industry but the path from a long list of potential partners to a successful deal is a long and complex one. Evaluate’s solutions provide the insight and support you need to navigate this path. From identifying strategic partnership opportunities, and streamlined due diligence to negotiation strategies and deal benchmarking.
Your BD&L objectives are core to your commercial success. By partnering with Evaluate, you can negotiate deals that drive return on investment and accelerate innovation.
Tailored support for your decision-making process
Our expert consultants partner with clients to address business questions throughout the BD&L process. They streamline decision-making to build commercially-focused pipelines and help address the balance between internal and external innovation, offering;
In-licensing candidate long list generation and prioritization
Out-licensing partner identification, prioritization and outreach
Asset valuation and due diligence
Innovation trends analysis
Pipeline tracking and competitor monitoring
Find out more about how our consultants can support your business development and portfolio strategy needs here.
Drive commercial, operational, and financial decisions with an accurate, view of the biopharma landscape.
Robust forecasting is a crucial tool for pharma and biotech companies. It guides strategies, reduces risk, and fuels innovation. Evaluate Pharma is the go-to source for consensus forecasts for pharma firms, investment banks, and consultancies.
You can access a richer, insight-driven perspective that uniquely connects consensus forecasts with pipelines across indications, therapeutic areas, and mechanisms of action.
Learn more about how Evaluate Pharma can provide market analysis to guide your commercial decisions.
